Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 7/20 | 0.48 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR7 | P34969 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743697 | 0.85 | CMA1 (0.49) | CMA1PFKFB4NPSR1L3MBTL1HTR2A | |
| SCHEMBL787942 | 0.84 | CMA1 (0.51) | CMA1PFKFB4NPSR1L3MBTL1HTR2A | |
| SCHEMBL788031 | 0.83 | NPSR1 (0.52) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL337593 | 0.82 | NPSR1 (0.62) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL787935 | 0.81 | PFKFB3 (0.50) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL3684064 | 0.80 | NPSR1 (0.44) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL787547 | 0.78 | L3MBTL1 (0.50) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL788489 | 0.78 | PFKFB3 (0.54) | CMA1PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL2113237 | 0.77 | CMA1 (0.36) | CMA1PFKFB4HTR2AHTR7DRD2 | |
| SCHEMBL1260774 | 0.77 | CMA1 (0.62) | CMA1PFKFB4NPSR1L3MBTL1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2828238-B1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP ZOO (PL) | 2016-05-25 | — | — | EP | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| US-7071220-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1486494-A1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVE | TOA EIYO LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. | 2003-12-11 | — | — | US | disclosed |
| EP-1325920-A1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | CMA1 4529/4885PFKFB4 469/4885NPSR1 466/4885 |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CMA1 3/4885PFKFB4 4092/4885NPSR1 88/4885 |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CMA1 3/4885PFKFB4 4092/4885NPSR1 88/4885 |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | CMA1 1/4885PFKFB4 2399/4885NPSR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.